Ligand Pharma Moves HQ, Elects Directors
Ticker: LGNZZ · Form: 8-K · Filed: Jun 17, 2024 · CIK: 886163
| Field | Detail |
|---|---|
| Company | Ligand Pharmaceuticals Inc (LGNZZ) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $550,000, $850,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-changes, relocation
Related Tickers: LGND
TL;DR
Ligand Pharma is moving its HQ to Florida and making board/exec changes.
AI Summary
Ligand Pharmaceuticals Inc. announced on June 14, 2024, a change in its principal executive offices from San Diego, CA to Jupiter, Florida. The company also reported on the election of directors and compensatory arrangements for certain officers, as well as the submission of matters to a vote of security holders.
Why It Matters
A change in principal executive offices can signal strategic shifts or operational adjustments for a company. The election of directors and executive compensation details are crucial for understanding corporate governance and management incentives.
Risk Assessment
Risk Level: low — The filing primarily concerns routine corporate governance matters and a change of address, with no immediate financial or operational risks highlighted.
Key Players & Entities
- LIGAND PHARMACEUTICALS INC (company) — Registrant
- Jupiter, Florida (location) — New principal executive offices
- San Diego, CA (location) — Former principal executive offices
FAQ
What is the new address for Ligand Pharmaceuticals Inc.'s principal executive offices?
The new address for Ligand Pharmaceuticals Inc.'s principal executive offices is 555 Heritage Drive, Suite 200, Jupiter, Florida 33458.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 14, 2024.
What are the main items reported in this 8-K filing?
This 8-K filing reports on the departure of directors or certain officers, election of directors, compensatory arrangements of certain officers, and the submission of matters to a vote of security holders.
What was Ligand Pharmaceuticals Inc.'s previous business address?
Ligand Pharmaceuticals Inc.'s previous business address was in San Diego, CA, with specific street and suite details not fully provided in the excerpt but the city and state are mentioned.
What is Ligand Pharmaceuticals Inc.'s state of incorporation?
Ligand Pharmaceuticals Inc. is incorporated in Delaware.
Filing Stats: 1,318 words · 5 min read · ~4 pages · Grade level 11.2 · Accepted 2024-06-17 16:02:51
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share LGND The Nasdaq Global Market
- $550,000 — calendar year generally may not exceed $550,000, which limit will be increased to $850,
- $850,000 — 0,000, which limit will be increased to $850,000 in the calendar year of his or her init
Filing Documents
- lgnd-20240614.htm (8-K) — 50KB
- 0000886163-24-000045.txt ( ) — 175KB
- lgnd-20240614.xsd (EX-101.SCH) — 2KB
- lgnd-20240614_lab.xml (EX-101.LAB) — 22KB
- lgnd-20240614_pre.xml (EX-101.PRE) — 13KB
- lgnd-20240614_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. Set forth below are the final voting results for the actions taken by the stockholders at the Annual Meeting. Proposal 1. The election of eight members of the Board for terms expiring at the 2025 annual meeting of stockholders. In accordance with the results below, each nominee was elected to serve as a director of the Company. Votes For Votes Withheld Broker Non-Votes Jason M. Aryeh 12,265,786 3,259,850 1,154,516 Todd C. Davis 15,244,447 281,189 1,154,516 Nancy R. Gray, Ph.D. 14,876,443 649,193 1,154,516 Jason Haas 15,284,373 241,263 1,154,516 John W. Kozarich, Ph.D. 14,024,170 1,501,466 1,154,516 John L. LaMattina, Ph.D. 14,981,023 544,613 1,154,516 Stephen L. Sabba, M.D. 14,839,776 685,860 1,154,516 Martine Zimmermann, Pharm.D. 15,067,611 458,025 1,154,516 Proposal 2. The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. In accordance with the results below, the selection of Ernst & Young LLP was ratified. Votes For Votes Against Abstentions Broker Non-Votes 15,908,245 754,285 17,622 - Proposal 3 . The approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers. In accordance with the results below, the proposal was approved. Votes For Votes Against Abstentions Broker Non-Votes 14,264,205 1,253,085 8,346 1,154,516 Proposal 4 . The approval of the Restated Plan. In accordance with the results below, the proposal was approved. Votes For Votes Against Abstentions Broker Non-Votes 9,926,628 5,577,590 21,418 1,154,516
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIGAND PHARMACEUTICALS INCORPORATED Date: July 17, 2024 By: /s/ Andrew Reardon Name: Andrew Reardon Title: Chief Legal Officer and Secretary